• RI Bio Appoints New Board Chair

    RI Bio, Rhode Island’s life sciences professional trade organization, announced they have appointed Jaimy Mauricio, MBA, as Board of Directors Chair effective July 1, 2024.

    Mauricio is Senior Director, Finance at Intellia Therapeutics, a leading genome editing company based in Cambridge. Their mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.  

    “Jaimy is a trailblazer at the nexus of finance and engineering, bringing a rigorously analytical mindset to our board,” said Carol Malysz, Executive Director of RI Bio. “He has devoted his career to harnessing his finance acumen, strategic vision, and leadership skills alongside his operations and engineering expertise to drive sound business decisions, enhance efficiencies, and maximize value.”

    Mauricio has two decades of experience in accounting, financial planning and strategic business analysis roles, plus seven years of engineering & operations experience in the biotech and polymer industries.

    “I am honored to be named RI Bio’s Board Chair and will work tirelessly to live up to the high standards set by Patrice,” Mauricio said. “This is an exciting time for life sciences in Rhode Island, with new state funding, new lab capacity coming online, and renewed emphasis on the sector. I am excited to lead significant growth for RI Bio as well as increase economic impact for our state through education, collaboration, and advocacy.”

    Prior to his current position, Mauricio served as the Operations Finance Controller at Rubius Therapeutics, with financial responsibilities for the company’s operations across its Cambridge, MA and Smithfield, RI sites. Prior to his finance career, Mauricio was fortunate to be a member of the engineering team overseeing the design, construction and placing into operations one of the world’s largest mammalian cell culture facilities in the world to produce monoclonal antibody medicines. Previously, he has held various finance roles at Amgen, Alexion Pharmaceuticals, and Takeda; as well as engineering roles at Amgen, Toray Plastics, and Acushnet Rubber Company. His experience includes leading global teams, financial planning and analysis, managing organizational units with $1B of annual spend, corporate financial consolidation and leading integration efforts following acquisitions. He holds an MBA from the University of Massachusetts and a BS in Chemical Engineering from Northeastern University.

    About RI Bio

    As the trade group and voice of southeastern New England’s life sciences industry, RI Bio fosters strategic partnerships that can create a healthier world and grow the life sciences economy. They serve as a catalyst for biotech industry acceleration, advocating for better policy, educating a strong life science workforce, collaborating with life sciences companies, hospitals, universities, capital sources and government agencies, sharing information and expertise, and promoting the advancement of science. The result is improved quality of life, advanced innovation and discovery, and a robust life sciences ecosystem.

/* AZU-560-12875 */ /* AZU-560-12875 */